Revenue: As of FY2026 Q2, the actual value is USD 3.043 B, beating the estimate of USD 2.973 B.

EPS: As of FY2026 Q2, the actual value is USD 2.84, beating the estimate of USD 2.5274.

EBIT: As of FY2026 Q2, the actual value is USD 475 M.

Second Quarter 2026 Financial Performance

Revenue

Quest Diagnostics Incorporated reported net revenues of $3,043 million for the second quarter ended June 30, 2026, marking a 10.2% increase from $2,761 million in the same period of 2025. Diagnostic Information Services revenues were $2,978 million, up 10.3% from $2,699 million in the prior year. The company experienced a 13.1% increase in requisition volume and a 13.0% increase in organic requisition volume, while revenue per requisition decreased by -2.8% compared to the second quarter of 2025.

Operating Income

Reported operating income for the second quarter of 2026 was $459 million, an increase of 4.6% from $438 million in 2025. The reported operating income as a percentage of net revenues was 15.1%, down from 15.9% in the prior year. On an adjusted basis, operating income reached $502 million, growing 7.8% from $466 million in 2025, with the adjusted operating income as a percentage of net revenues at 16.5%, compared to 16.9% in 2025.

Net Income

Net income attributable to Quest Diagnostics Incorporated was $320 million, a 13.4% increase from $282 million in the second quarter of 2025. Adjusted net income attributable to Quest Diagnostics Incorporated was $350 million, up 17.3% from $298 million in the same period of 2025.

Cash Flow and Capital Expenditures

Cash provided by operations for the second quarter of 2026 was $597 million, an increase of 9.7% from $544 million in 2025. Capital expenditures rose by 27.0% to $138 million from $108 million in the prior year.

Six Months Ended June 30, 2026 Financial Performance

Revenue

For the six months ended June 30, 2026, Quest Diagnostics Incorporated reported net revenues of $5,938 million, an increase of 9.7% from $5,413 million in 2025. Diagnostic Information Services revenues were $5,810 million, up 9.9% from $5,288 million in the previous year. Requisition volume increased by 12.0% and organic requisition volume by 11.9%, while revenue per requisition decreased by -2.1% year-over-year.

Operating Income

Reported operating income for the first six months of 2026 was $858 million, a 9.4% increase from $784 million in 2025. The reported operating income as a percentage of net revenues was 14.4%, a slight decrease from 14.5% in 2025. Adjusted operating income was $949 million, up 8.8% from $872 million in the prior year, with the adjusted operating income as a percentage of net revenues at 16.0%, compared to 16.1% in 2025.

Net Income

Net income attributable to Quest Diagnostics Incorporated for the six-month period was $572 million, a 13.9% increase from $502 million in 2025. Adjusted net income attributable to Quest Diagnostics Incorporated was $631 million, up 14.9% from $549 million in the same period of 2025.

Cash Flow and Capital Expenditures

Cash provided by operations for the six months ended June 30, 2026, was $875 million, a 1.9% increase from $858 million in 2025. Capital expenditures increased by 12.1% to $252 million from $225 million in the prior year.

Operational Highlights

Quest Diagnostics Incorporated continued to advance its Co-Lab Solutions implementation and joint venture laboratory with Corewell Health in Michigan, and developed new capabilities in kidney care through its collaboration with Fresenius Medical Care in the United States. The company generated robust revenue growth through questhealth.com and its consumer, wearable, and wellness partners, and achieved double-digit revenue growth in several areas of Advanced Diagnostics, including Quest AD-Detect® blood tests for Alzheimer’s disease and advanced cardiometabolic and endocrine tests. Additionally, Quest Diagnostics Incorporated received New York State approval for its Haystack MRD® test and became the largest reference lab to utilize Flatiron Health’s OncoEMR® Molecular Profiling Integration (MPI) platform for select cancer tests. The company also extended automation solutions in cervical cancer screening and front-end specimen processing to additional labs, and launched IntelliDraw™ to guide clinical staff of physician customers through specimen collection.

Full Year 2026 Outlook

Quest Diagnostics Incorporated has raised its full year 2026 guidance, now expecting net revenues to be between $11.95 billion and $12.05 billion, representing an increase of 8.3% to 9.2%. Cash provided by operations is anticipated to be approximately $1.80 billion, with capital expenditures remaining approximately $550 million. The full year adjusted effective tax rate is expected to be consistent with 2025 due to the favorable resolution of various tax contingencies in the second quarter.